Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, explains how 2nd line patients who received Keytruda or other PD-L1 targeting agents can be treated.
Treatment in 2nd Line Setting After 1st Line PD-L1 Targeting
